Over the past decade, cell, apheresis and gene therapies have progressed from experimental concepts to established components of routine clinical care. What once appeared to be an ‘overnight success’ has been built on decades of scientific discovery, clinical translation and system-level innovation. For patients with otherwise refractory disease – and for the donors whose generosity underpins some of these therapies – the impact has been transformative.
Enhancing outcomes for patients and donors: cell, apheresis and gene therapies
July 2026
James Griffin reviews current progress in cellular and gene therapies and the need for equitable access.